$73.10
1.021.42%
Monopar Therapeutics Inc
MNPRNASDAQ
Monopar Therapeutics (MNPR) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.65 | $-0.93 | $-0.54 | $-0.42 |
| Actual | $-0.62 | $-0.46 | $-0.61 | $-0.48 |
| Surprise | +4.62% | +50.5% | -13.0% | -14.3% |
| Revenue | ||||
| Estimate | — | — | — | — |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | — | — | — | — |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.85 | $-1.13 | $-0.76 | $-0.82 |
| Revenue | ||||
| Consensus | — | — | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $-0.62 | $-0.65 | 4.62 % |
| Q1 | May 14, 2026 | $-0.46 | $-0.93 | 50.5 % |
| Q4 | Mar 27, 2026 | $-0.61 | $-0.54 | -13.0 % |
| Q3 | Nov 13, 2025 | $-0.48 | $-0.42 | -14.3 % |
